How open science funding supports drug discovery in Canada

Drug discovery is slow, expensive, and risky. In Canada, open science funding helps lower these barriers. It does this by supporting early-stage research and requiring data to be shared openly. Programs like Developing Medicines through Open Science (DMOS) focus on preclinical drug development. They aim to turn publicly funded research into therapies for unmet medical needs.

Most drug candidates fail before reaching clinical trials. By funding research at the preclinical stage and making results public, Canada helps more scientists reuse, improve, or commercialize promising discoveries.

If you’re exploring funding for your life sciences project, it’s smart to check which programs fit your research stage and business type. GrantHub can help you compare open science programs across Canada.

How open science funding works in Canadian drug discovery

Open science funding supports drug discovery by linking funding to open sharing and teamwork. Teams that receive funding must share their data, methods, and findings as they work. This means public money supports research that others can use and build on.

Developing Medicines through Open Science (DMOS)

The Developing Medicines through Open Science (DMOS) program is a federal initiative delivered by Conscience, part of the Structural Genomics Consortium (SGC).

What DMOS funds

DMOS supports preclinical drug development projects that:

Address a clear unmet medical need
Operate within Technology Readiness Levels (TRL) 2–6
Generate:
- New drug candidates, or
- Proof-of-concept for open-science-based drug development
Create economic activity and SME participation in Canada

Who is eligible

To qualify for DMOS funding, projects must:

Include at least one Canadian small or medium-sized enterprise (SME)
Show matching funds from sources other than DMOS
Agree to open science data sharing under the program’s Open Science Policy
Work together with Conscience during both the Letter of Intent (LOI) and full proposal stages

Projects are not eligible if they fall outside TRL 2–6, do not address an unmet medical need, or do not agree to share data openly.

This approach helps the whole life sciences community by making results available for others to build on.

Non-financial open science support: Centre for Drug Research and Development (CDRD)

Open science funding is not always direct cash. The Centre for Drug Research and Development (CDRD), part of adMare Bioinnovations, supports drug discovery by offering access to expertise, facilities, and partnerships.

CDRD offers:

Scientific research and drug development facilities in Vancouver
Commercial and regulatory expertise
Connections to industry and academic partners

CDRD support is available to life sciences companies, including startups and scaling SMEs, but it does not provide direct grant funding. Instead, it helps reduce risk in early research so projects are more likely to attract public or private funding later.

Why open science funding matters for Canadian SMEs

For Canadian biotech and life sciences SMEs, open science funding changes how early drug discovery is done.

Key benefits include:

Lower early-stage risk: Shared data stops teams from repeating failed experiments.
Faster validation: Open results let others review and help sooner.
Stronger funding pathways: Programs like DMOS require SME participation, bringing companies into publicly funded research earlier.
Public trust: Open science matches what Canadians expect for transparency in health research.

GrantHub’s eligibility matcher can help you quickly filter open science and life sciences programs by province, TRL level, and business type.

Common mistakes to avoid

Ignoring open science requirements
DMOS requires full compliance with its Open Science Policy. Holding back data or IP can make a project ineligible.
Applying outside the supported TRL range
Projects below TRL 2 or beyond TRL 6 are not eligible for DMOS, even if the science is strong.
Missing the SME requirement
DMOS projects must include at least one Canadian SME. Academic-only teams are not eligible.
Underestimating matching funds
Matching funding is mandatory. Weak or uncertain matching support can stop an application from moving forward.

Frequently Asked Questions

Q: What is open science in drug discovery?
Open science means sharing research data, methods, and results openly instead of keeping them secret. In drug discovery, this helps reduce duplication and speeds up progress, especially in early research stages.

Q: Does DMOS fund clinical trials?
No. DMOS supports preclinical research only, within TRL 2–6. Clinical trials fall outside the program’s scope.

Q: Do SMEs lose intellectual property under open science funding?
Under DMOS, results must be openly shared, which limits traditional IP strategies. In return, SMEs gain early validation, visibility, and collaboration opportunities.

Q: Is DMOS funding available across Canada?
Yes. DMOS is a federal program and supports eligible projects anywhere in Canada, as long as program criteria are met.

Q: Can startups work with CDRD without DMOS funding?
Yes. CDRD works with life sciences companies at different stages, including startups, by providing expertise and facilities rather than direct funding.

Next steps

Open science funding is playing a bigger part in how medicines are developed in Canada, especially at the preclinical stage. If your business or research team works in life sciences, the next step is to find which programs match your TRL, partnership setup, and data-sharing approach.

GrantHub tracks hundreds of active grant and support programs across Canada — check which open science and drug discovery programs match your business profile.

How open science funding supports drug discovery in Canada